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Abstract Decisions by third-party payors that are restrict-
ing delivery of appropriate IgG treatment for primary im-
munodeficiency disease (PIDD) are summoning action from
patients, physicians, and their organizations to ensure that
high quality treatment remains accessible. Some of the
strongest advocacy to date is from patient organizations,
such as the Immune Deficiency Foundation (IDF), which
strive to educate stakeholders on key issues that determine
patient access to appropriate IgG treatment. These issues
include the ability to choose the appropriate site of care
based on a patient’s experience and circumstance and great-
er awareness of product choice. Advocacy by physicians on
these issues at the local level is needed, as are national
efforts by organizations such as the American Academy of
Allergy, Asthma & Immunology and their regional societies.
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Introduction
The preceding article in this supplement provided clear
support for the view that policy decisions by third-party
payors restrict delivery of appropriate immunoglobulin G
(IgG) treatment for patients with primary immunodeficiency
disease (PI) and that effective action to reverse these policies
requires coordinated actions by patients, physicians, and
advocacy groups. Initiatives at both the local and national
levels are important for ensuring that patients with PI retain
or, in some cases, regain access to appropriate care with
IgG. This article reviews advocacy resources and activities
undertaken at the national and local levels that have im-
proved appropriate access to care.
Advocacy Resources
Treatment Guidelines
Treatment guidelines for the management of patients with PI
provide an important basis for advocacy efforts. These rec-
ommendations establish the standard of care for PI patients
and are thus important tools for challenging insurance com-
pany policies that are inconsistent with evidence-based med-
icine. The most prominent guideline in the United States is
"The use of intravenous immunoglobulin and adjunctive ther-
apies in the treatment of primary immunodeficiencies: A
working group report of and study by the Primary Immuno-
deficiency Committee of the American Academy of Allergy,
Asthma & Immunology (AAAAI)" [1]. These guidelines are
currently under revision, and an update will be submitted in
2012. The Canadian Blood Services and National Advisory
Committee has published a similar comprehensive document
highlighting the use of IgG therapies for PI [2].
The AAAAI Intravenous Ig (IGIV) Toolkit
The AAAAI IGIV Toolkit, an adjunct to the treatment guide-
lines published by this group, is another important resource
that can be used for educating insurers and regulators; it also
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effective IGIV administration. The development of this Tool-
kit was stimulated by anonymous results from an AAAAI
survey indicating that >95 % of respondents believed that
current reimbursement standards posed a risk to the health of
their PI patients [3]. This Toolkit was approved by the AAAAI
Board of Directors, the Clinical Immunology Society, and the
Immune Deficiency Foundation (IDF); it provides an example
of how these national organizations can work together to
achieve an important common goal.
The AAAAI IGIV Toolkit sets forth 8 guiding principles
for the safe, effective, and appropriate use of IGIV for PI
(Table I) [4]. Although the Toolkit was not developed exclu-
sively to educate insurers, it does address key areas in which
they have created barriers to care for PI patients. The Toolkit
emphasizes that IGIV treatment is appropriate for patients
with PI, improves quality of life, and may even be lifesaving.
It also states that IGIV treatment should not be interrupted
once a definitive PI diagnosis has been established. The Tool-
kit provides guidance regarding IGIV dosing. The generally
accepted IGIV starting dose is 400–600 mg/kg every 3–
4 weeks, and the route of IgG administration must be based
upon patient characteristics and patient preference [4]. It
should be noted that the use of IGSC has been increasing in
the US in recent years.
The Toolkit also challenges the concept that a single IgG
product can be used for all patients and that formulary restric-
tion to control costs is a rational approach to care. The Toolkit's
guiding principles state that IGIV is not a generic drug and that
IGIV products are not interchangeable. A specific IGIV prod-
uct needs to be matched to patient characteristics to ensure
safety. Also, a change of IGIV product should occur only with
the active participation of the prescribing physician [4].
In addition to the 8 principles, the Toolkit contains back-
ground information, a detailed explanation of each principle, a
position paper on the use of IGIV, the current AAAAI guide-
lines, and site-of-care treatment recommendations. Also in-
cluded is a template for letters to contact medical directors
advocating coverage for IGIV. The IGIV Toolkit is currently
being revised with the aim of including more information
about IGSC and the risks associated with product switching.
Case Studies: National and Local Intervention
National Advocacy: Restrictive Formulary for IgG Products
In December 2010, a major insurance company issued a
special bulletin stating that IgG products were considered
clinically equivalent and interchangeable and that, effective
April 1, 2011, a formulary for IgG with only one preferred
product for both IGIV and IGSC would be instituted. To
access a nonpreferred IgG product, a patient must have a
documented drug therapy failure with the preferred product.
The IDF Medical Advisory Committee (MAC) responded to
this action with a product choice resolution stating that 1) IgG
therapies are not generic; 2) a policy that provides access to
alternate therapies only after a patient has suffered an adverse
event is unacceptable; 3) the incidence of adverse reactions
increases when a patient changes therapies; and 4) not all
brands of IgG will always be immediately available, and
restricting physicians to a single approved product could lead
to delays in treatment [5]. IDF sent a letter and the IDF MAC
resolution to the insurer and initiated discussions with them.
Because April 1 was less than a month away and IDF had
heard of no official changes to the initial policy, IDF
launched a campaign on March 16, 2011 with a press release
in local markets and the launch of a blog. IDF reached out to
other patient organizations and local medical groups for
Table I Principles in the AAAAI IGIV Toolkit [4]
1. Indication - IGIV therapy is indicated as replacement therapy for patients with PI characterized by absent or deficient antibody production. This
is an FDA-approved indication for IGIV for which all currently available products are licensed.
2. Diagnoses - There are a large number of PI diagnoses for which IGIV is indicated and recommended. Many have low total levels of IgG, but
some have a normal level with documented specific antibody deficiency.
3. Frequency of IGIV treatment - IGIV is indicated as continuous replacement therapy for primary immunodeficiency. Treatment should not be
interrupted once a definitive diagnosis has been established.
4. Dose - For patients with primary immunodeficiency, IGIV is indicated at a starting dose of 400–600 mg/kg every 3–4 weeks. Less frequent
treatment, or use of lower doses, is not substantiated by clinical data.
5. IgG trough levels - IgG trough levels can be useful in some diagnoses to guide care but are NOT useful in many and should NOT be a
consideration in access to IGIV therapy.
6. Site of care - The decision to infuse IGIV in a hospital, hospital outpatient, community office, or home-based setting must be based upon the
clinical characteristics of the patient.
7. Route - Route of immunoglobulin administration must be based upon patient characteristics. The majority of patients are appropriate for
intravenous, while a subset is appropriate for subcutaneous therapy.
8. Product - IGIV is not a generic drug, and IGIV products are not interchangeable. A specific IGIV product needs to be matched to patient
characteristics to ensure patient safety. A change of IGIV product should occur only with the active participation of the prescribing physician.
Adapted from the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology [4].
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support and was joined by the Pennsylvania Allergy and
Asthma Association and the Pennsylvania Medical Society.
In addition, IDF identified patients in the community who
would be impacted by the policy and who could mobilize
with the media campaign.
On March 18, 2011, the insurance company responded to
these actions by making the following changes in its "fail-
first" policy for switching from the preferred IgG: 1)
patients who had an adverse reaction to the preferred prod-
uct in the past were not required to try it again; 2) patients
who had medical evidence that a switch to the preferred
product would likely cause an adverse reaction due to prod-
uct characteristics (e.g., sugar content, IgA content, sodium
content) are not required to use it; 3) patients with docu-
mented objective laboratory evidence (e.g., IgA level) that
would predispose them to significant adverse events
were not required to use the preferred product; and 4)
patients <18 years of age who were currently stable on
a nonpreferred product were not required to switch.
IDF responded to these changes by stating that, although
the changes were a good step forward, they did not provide
sufficient protection for adult patients already stabilized on
an IgG therapy that was not the insurer’s preferred brand.
IDF initiated a call to action that resulted in 650 letters being
sent to the insurance company’s manager. On March 28,
2011, the insurer stated that it would “grandfather,” or
continue to cover, all IgG products not on its preferred
formulary for current health plan members with PI. For
new members who join the health plan and receive an IgG
product other than the preferred product, the insurer will
individually evaluate each case based on clinical rationale.
Local Advocacy: Clinical Care Guidelines that Impacted
Access to Care for Patients
In March 2009, a large health plan in Minnesota began
denying claims for IgG for a number of PI patients. This
prompted an IDF-led letter-writing campaign to the health
plan, with copies to the governor, the state attorney general,
and the insurance commissioner. In March 2010, the Mid-
west Immunology Center in Minnesota withdrew from the
health plan network in protest of their policies; this resulted
in patients being sent to in-network physicians, some of
whom had little, if any, experience in the management of
patients with PI. Members of the IDF MAC and AAAAI PI
Committee jointly reviewed the health plan guidelines and
sent a letter pointing out ways in which the policy did not
reflect the standard of care recommended by the AAAAI
and was limiting access to care. The cooperative effort
between the IDF MAC, the AAAAI, and the health plan
led to the AAAAI deciding to update their IgG guidelines,
with the health plan ultimately updating their policies in
April 2011.
Lessons Learned
Experience from these and other cases has provided impor-
tant lessons for avoiding and responding to problems of
appropriate access to IgG. Problems with treatment approval
may be avoided by providing the appropriate diagnosis
(e.g., common variable immunodeficiency, rather than
hypogammaglobulinemia or dysgammaglobulinemia) so
that it may be properly coded for the insurance provider,
as well as by including pertinent clinical and laboratory
information in a submission packet. Inclusion of relevant
medical literature will speed prior authorization. If authori-
zation is denied, it is important to gain access to an insur-
ance company medical director who can competently
discuss the relevant medical issues. If this fails, a peer-to-
peer review can be requested in which a physician who
treats patients with immunodeficiency may be included in
the process. It is very important to have information regard-
ing current standards of care available to support a request
for treatment (e.g., AAAAI Committee on Immune Defi-
ciency guidelines on immunoglobulins [1]).
The results from the case studies summarized in the
preceding section underscore the importance of both
local and national advocacy groups to force changes in
insurer policies that negatively affect patient care. Local
advocacy may include actions (e.g., letter-writing cam-
paigns, telephone campaigns) by family groups affiliated
with the IDF and by the Jeffrey Modell Foundation
(JMF), a global nonprofit organization dedicated to ear-
ly diagnosis, meaningful treatments, and, ultimately,
cures for PI achieved through research, physician edu-
cation, public awareness, advocacy, patient support, and
newborn screening [6]. In addition, supporting local
legislation may be helpful in forcing insurance compa-
nies to evaluate their policies and change those that do
not conform to best medical practices. For example,
legislation proposed in Minnesota (Minnesota Statutes,
chapters 62Q; 151; Coverage Of Plasma Protein Thera-
pies And Home Nursing Services) states that any health
plan offered by a health plan company must carry all
FDA-approved plasma protein therapies in the formu-
lary, provide coverage for home nursing services, com-
plete pre-authorization within 24 h or one business day,
and provide the option of receiving covered services at
more than one pharmacy. In addition, this legislation
states that the Board of Pharmacy shall promulgate rules
that include standards established by the MACs of the
patient groups and professional societies representing
individuals with PI.
National advocacy may include actions by the IDF
and its MAC, the AAAAI Committee on PI, and public
awareness campaigns sponsored by the IDF and/or the
JMF.
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Conclusions
Physicians and other healthcare professionals involved in
the care of patients with PI should be aware of policies that
limit access to appropriate care. It is often difficult for
individual providers to effectively combat insurer deci-
sions that limit treatment, but local, regional, and national
resources are available to help address these problems. It
is important for healthcare professionals and advocacy
groups to monitor regulation and legislation aimed at
governing insurance companies and to intervene when
needed to make policies consistent with current standards
of care.
Discussion
Questions for the audience at the symposium underscored
the difficult decisions insurers impose on physicians. For
example, physicians may be required to repeatedly dem-
onstrate that patients indeed have PI in order to gain
reauthorization for treatment. Symposium attendees were
given the following scenario: "The patient tells you that
their IGIV product is being switched to another ‘brand’
that has been previously a problem for him or her. What
would you do?" Nearly 90 % of 54 respondents stated
that they would pull the documentation of the tolerability
issue on the previous product to discuss with the insur-
ance medical director. This suggests that many attendees
at the symposium understood the best approach to nego-
tiation in these situations.
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